

# Dual Mechanisms of Regulation of Type I Iodothyronine 5'-Deiodinase in the Rat Kidney, Liver, and Thyroid Gland

## Implications for the Treatment of Hyperthyroidism with Radiographic Contrast Agents

Donald L. St. Germain

With the technical assistance of Ayse Atasoylu

Departments of Medicine and Physiology, Dartmouth Medical School, Hanover, New Hampshire 03756

### Abstract

Alterations in thyroid hormone status and the administration of radiographic contrast agents can markedly influence iodothyronine metabolism and, in particular, the activity of type I 5'-deiodinase (5'DI). In the present studies, the mechanisms responsible for these effects have been reassessed. As previously reported, the addition of iopanoic acid (IOP) to broken cell preparations resulted in a competitive pattern of 5'DI inhibition. However, the *in vivo* administration to rats of IOP or 3,3',5'-triiodothyronine ( $rT_3$ ) resulted in a noncompetitive pattern of inhibition of 5'DI in the liver, kidney, and thyroid gland, whereby marked decreases in maximal enzyme velocity ( $V_{max}$ ) were noted, with no change in the value of the Michaelis-Menten constant. In rats rendered hyperthyroid by the injection of 3,5,3'-triiodothyronine ( $T_3$ ), 5'DI activity was significantly increased in the liver and the kidney. The administration of IOP to these thyrotoxic animals resulted in a rapid loss of enzyme activity characterized by an approximate 80% decrease in 5'DI  $V_{max}$  values in both tissues. Furthermore, this inhibitory effect persisted for longer than 60 h after a single IOP injection. IOP administration also decreased 5'DI  $V_{max}$  levels in the thyroid gland by 52%. In other experiments, treatment of intact Reuber FAO hepatoma cells with IOP or  $rT_3$  induced a rapid decrease in 5'DI  $V_{max}$  levels. In cells treated with cycloheximide, these agents enhanced the rate of disappearance of enzyme activity by > 12-fold, indicating a predominant effect on accelerating the rate of enzyme inactivation and/or degradation. These studies demonstrate that iodothyronines and other iodinated compounds have complex regulatory effects on 5'DI that entail alterations in the rates of both enzyme activation and inactivation. The previously accepted concept that  $rT_3$  and IOP impair thyroxine ( $T_4$ ) to  $T_3$  conversion *in vivo* by acting as competitive inhibitors is an oversimplification. Rather, the clinically beneficial effects of administering these agents to patients with hyperthyroidism may result primarily from the rapid and prolonged inactivation of 5'DI which occurs in the thyroid gland and peripheral tissues.

Portions of this work appeared in abstract form and were presented at the 69th annual meeting of the Endocrine Society (June 1987, Indianapolis, IN) and the 62nd meeting of the American Thyroid Association (September 1987, Washington, DC).

Address all correspondence to Dr. Donald L. St. Germain, Division of Endocrinology, Dartmouth Medical School, Hanover, NH 03756.

Received for publication 8 September 1987 and in revised form 17 November 1987.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/88/05/1476/09 \$2.00

Volume 81, May 1988, 1476-1484

### Introduction

The hyperthyroid state associated with Graves' disease is characterized by a marked increase in the rate of both the thyroidal secretion and the peripheral production of 3,5,3'-triiodothyronine ( $T_3$ )<sup>1</sup> (1). The resultant elevations in the circulating and tissue  $T_3$  concentrations lead to functional changes in a number of organ systems and thus produce the characteristic signs and symptoms of this disorder.

Alterations in thyroid hormone status also have important and direct "autoregulatory" effects on the cellular processes that metabolize these hormones (2). In the rat, hyperthyroidism results in a marked increase in the rate of "local"  $T_3$  production in the liver (3, 4). This effect is secondary, in part, to an increase in activity of type I 5'-deiodinase (5'DI), the principal enzymatic process responsible for hepatic thyroxine ( $T_4$ ) to  $T_3$  conversion (5). In contrast to this activating effect of thyroid hormones on 5'DI in the liver (and kidney [6]), type II 5'-deiodinase (5'DII) activity in the anterior pituitary gland and central nervous system is suppressed in hyperthyroid animals, and  $T_3$  neogenesis in these tissues is markedly decreased (2, 3). The autoregulatory effects of thyroid hormones on 5'DI and 5'DII thus differ significantly. As a consequence, the 5'DI present in the liver and kidney is likely to be the principal process mediating the extrathyroidal conversion of  $T_4$  to  $T_3$  in the hyperthyroid state.

Radiographic contrast agents such as iopanoic acid (IOP) and sodium ipodate (NaIp) inhibit  $T_4$  to  $T_3$  conversion in man (7-9) and experimental animals (10-12), and offer an alternative to the thionamides in the treatment of Graves' disease (13, 14). When administered to hyperthyroid patients, these agents induce a marked decrease in the serum  $T_3$  concentration which occurs more rapidly than that noted after the administration of stable iodine (15) or 6-*n*-propyl-2-thiouracil (PTU) (16). The rapidity with which radiographic contrast agents lower  $T_3$  levels may be of considerable clinical importance. In a recent study of thyrotoxic patients with severe cardiac manifestations, the amelioration of clinical symptoms after NaIp administration paralleled the fall in serum  $T_3$  levels; significant improvements in several cardiovascular parameters were noted as early as 3 h after a single dose (17).

In tissue homogenates, IOP and NaIp act as competitive inhibitors of both 5'DI (18-20) and 5'DII (21, 22), and this has previously been assumed to be the mechanism whereby they

1. Abbreviations used in this paper: BW, body weight; 5'DI, type I iodothyronine 5'-deiodinase; 5'DII, type II iodothyronine 5'-deiodinase; IOP, iopanoic acid; MMI, methimazole; NaIp, sodium ipodate; prot, protein; PTU, 6-*n*-propyl-2-thiouracil;  $rT_3$ , 3,3',5'-triiodothyronine;  $T_3$ , 3,5,3'-triiodothyronine;  $T_4$ , thyroxine; TSH, thyroid-stimulating hormone.

inhibit  $T_3$  neogenesis *in vivo*. We have recently demonstrated, however, that these agents inhibit  $T_4$  to  $T_3$  conversion in the anterior pituitary gland and cerebral cortex *in vivo* by non-competitively and irreversibly inactivating the 5'DII enzyme (23). This process of inactivation involves a unique mechanism of enzyme regulation that may be initiated by the direct interaction of ligands (e.g., substrates such as  $T_4$  or 3,3',5'-triiodothyronine [reverse  $T_3$ ,  $rT_3$ ], or competitive inhibitors such as IOP) with the 5'DII active site. Furthermore, this ligand-induced inactivation of 5'DII is modulated by the cellular thiol/disulfide balance (23).

These findings regarding the regulation of 5'DII prompted us to investigate the mechanisms whereby thyroid hormones, radiographic contrast agents, and sulfhydryl oxidizing agents regulate 5'DI in several tissues of the rat. Our results demonstrate that 5'DI is regulated in a manner considerably more complex than previously believed, and that this enzymatic process in the liver, kidney, and thyroid gland is subject to ligand-induced inactivation in a fashion analogous to that previously delineated for 5'DII.

## Methods

**Materials.** Iodothyronines were obtained from Henning Co. (West Berlin, FRG) or Calbiochem-Behring Diagnostics, American Hoechst Corp. (La Jolla, CA) and were of the highest purity commercially available. IOP was kindly provided by the Sterling-Winthrop Research Institute (Rensselaer, NY). 3'- or 5'- $^{125}I$ -labeled  $rT_3$  (SA  $\sim 830 \mu Ci/\mu g$ ) was obtained from New England Nuclear (Boston, MA).

**Animal experiments.** Male Sprague-Dawley rats (175–200 g) were used in all experiments and were obtained from Charles River Breeding Laboratory, Inc. (Wilmington, MA). Animals were housed under conditions of controlled lighting and temperature and were given free access to food. In one experiment, rats were rendered hypothyroid and goitrous by the inclusion of 200  $\mu g/ml$  methimazole (MMI) in their drinking water for 4 wk. Animals so treated stopped gaining weight after 10 d, and the wet weight of their individual thyroid glands was increased threefold over that of euthyroid control animals (control,  $14 \pm 1$  mg/gland; MMI,  $41 \pm 2$ ;  $P < 0.001$ ). In other experiments, thyroidectomized rats (with the parathyroid glands reimplanted) were obtained from the same supplier and were used for experiments 8 wk after surgery. Before killing, animals received single or multiple injections of  $T_3$ ,  $rT_3$ ,  $T_4$ , and/or IOP according to the experimental protocols described below. Control animals received equivalent volumes of the vehicle solution (propylene glycol, 0.1 N NaOH, 0.25 M NaCl [50:42:8 vol/vol]).

Renal, hepatic, and/or thyroidal tissue were harvested from individual animals and homogenized in 10 vol of assay buffer (0.25 M sucrose, 0.02 M Tris/HCl, pH 7.0, 1 mM EDTA) using either a motorized Teflon pestle (kidney and liver) or a ground glass homogenizer (thyroid). The homogenates were centrifuged at 1,000  $g$  and the supernatant diluted 1:40 to 1:800 with assay buffer. All preparative procedures were performed at 0–4°C. 5'DI activity was determined immediately in the diluted supernatant by a kinetic analysis in which the production rate of  $^{125}I^-$  from  $^{125}I-rT_3$  was measured in the presence of 20 mM dithiothreitol using a modification of the methods of Leonard and Rosenberg (24) and McCann et al. (25). At each concentration of  $^{125}I-rT_3$ , duplicate aliquots of the diluted supernatant (40  $\mu l$  containing 0.5–10  $\mu g$  of protein) were incubated at 37°C for 40 min and the reaction was then terminated by the addition of 12  $\mu l$  of an ice-cold BSA solution (40 mg/ml) plus 120  $\mu l$  of an ice-cold 20% TCA solution. Other aliquots were kept at 0–4°C and terminated immediately after adding the  $^{125}I-rT_3$  to determine basal  $^{125}I^-$  content. The  $^{125}I^-$  present in the supernatant fraction of the terminated reaction mixture was separated by ion-exchange chromatography using an AG50W-X8

(H+) column (mesh size, 200–400; bed size,  $0.7 \times 4$  cm; Bio-Rad Laboratories, Richmond, CA) equilibrated and washed with 10% acetic acid. The  $^{125}I^-$  in the column effluent was counted in a gamma counter. As quantified by paper chromatography or TLC (see below), equal molar quantities of 3,3'-diiodothyronine and  $I^-$  were produced from  $^{125}I-rT_3$  in the homogenates of kidney, liver, and thyroid tissue. No  $^{125}I^-$  was released in tissue-free incubations performed at 37°C. 5'DI activity was expressed as picomoles of  $^{125}I^-$  released per minute per milligram protein after multiplying by a factor of two to correct for the random labeling of  $^{125}I-rT_3$  at the 3' or 5' position. Kinetic data were analyzed by double reciprocal and Eadie-Hofstee plots (26) using the average substrate concentration during the 40-min incubation period as suggested by Lee and Wilson (27). The value of the  $K_i$  was calculated by replotting the slope of the double reciprocal plot vs. the concentration of competitive inhibitor. On such a plot, the  $K_i$  value is represented by the negative value of the  $x$ -intercept (28).

**Cell culture experiments.** Reuber FAO rat hepatoma cells were a gift from Dr. Lee A. Witters (Dartmouth Medical School, Hanover, NH) and were routinely grown in 75-cm<sup>2</sup> plastic flasks and 60- and 100-mm plastic culture dishes using RPMI 1640 culture medium supplemented with 5% FCS, 5% calf serum, 100 U/ml penicillin, and 100  $\mu g/ml$  streptomycin. In some studies, cells were transferred and maintained for 24–48 h in serum-free RPMI 1640 medium before experimentation. Other experiments were performed with cells incubated in serum-free medium which was also glucose-free. Experiments were performed with cells at the confluent stage of growth and 24 h after the last medium change. At various times after the addition of agents to the FAO cell cultures, the medium was aspirated and the cells were washed twice with PBS. The cells were then harvested by scraping with a rubber policeman into assay buffer and sonicated using a sonic dismembrator (Artek Systems Corp., Dynatech Corp., Farmingdale, NY). In experiments in which cells were incubated with diamide, the wash buffer and assay buffer contained 5 mM DTT. The sonicate was then centrifuged at 14,000  $g$  and aliquots of the supernatant (40  $\mu l$  containing  $\sim 25$ –100  $\mu g$  of protein) were used immediately for the determination of 5'DI activity as described above. All preparative procedures were carried out at 0–4°C. As quantified by paper chromatography, equal molar quantities of 3,3'- $T_2$  and  $I^-$  were produced from  $^{125}I-rT_3$  in the FAO cell sonicates.

**Other determinations.** The effect of cycloheximide on protein synthesis in FAO cells was determined by quantitating [ $^3H$ ]leucine incorporation into TCA-precipitated material according to the method of Scornik et al. (29).

Ascending paper chromatography was performed using a tertial amyl alcohol/2 N ammonium hydroxide (1:1) solvent system as described by Galton and Hiebert (30).

TLC was performed as described by van Doorn et al. (31) using 20  $\times$  20 cm aluminum sheets coated with Silicagel-60 (E. Merck, Darmstadt, FRG) and a solvent system consisting of 25% ammonium-methanol-chloroform (3:20:40 vol/vol).  $R_f$  values for the iodinated compounds of interest were: 0.31 for  $rT_3$ , 0.42 for 3,3'- $T_2$ , and 0.67 for  $I^-$ .

Protein concentrations were determined by the method of Lowry et al. (32). Aliquots of tissue samples containing DTT were precipitated with TCA before the determination of protein content (33).

All results are given as the mean  $\pm$  SE. Statistical analysis was performed using the paired and unpaired  $t$  test with the Bonferroni correction applied when multiple comparisons were made (34). Alternatively, Dunnett's  $t$  test was used when multiple comparisons were made with a control group (35).

## Results

**Regulation of 5'DI in kidney and liver.** As previously reported by other investigators (18–20), IOP acted as a competitive inhibitor of 5'DI *in vitro*. Thus, the addition of increasing concentrations of IOP to kidney homogenates from a euthyroid animal resulted in a series of kinetic curves that inter-

sected at the  $y$ -axis on a double reciprocal plot (Fig. 1). Slope-replots of such data (Fig. 1, inset) from two experiments yielded  $K_i$  values of 8 and 10  $\mu\text{M}$ .

The *in vivo* administration of IOP to thyroidectomized rats resulted in an entirely different pattern of inhibition. Double reciprocal plots of kinetic data obtained in renal homogenates from individual animals injected 3 h previously with IOP revealed a decrease in  $V_{\text{max}}$  with no change in the value of the  $K_m$ , indicating a noncompetitive mechanism of inhibition (Fig. 2). As shown in Table I, IOP dosages of 0.04 and 4 mg/100 g body weight (BW) inhibited 5'DI  $V_{\text{max}}$  values by 52 and 66%, respectively. The finding that  $K_m$  values were unchanged in this (Table I), as well as in subsequent experiments, indicates that the amount of IOP carried over into the *in vitro* 5'DI assay system was insufficient to cause competitive inhibition of  $^{125}\text{I-rT}_3$  deiodination.

The effects of the chronic administration of  $\text{T}_3$ ,  $\text{rT}_3$ , and IOP on the regulation of 5'DI in the kidney and liver were examined in a second group of thyroidectomized rats (Fig. 3). Twice daily, injections of  $\text{rT}_3$  (50  $\mu\text{g}/100$  g BW) or IOP (100  $\mu\text{g}/100$  g BW) resulted in a marked and significant decrease in  $V_{\text{max}}$  values in both tissues. In contrast, the administration of  $\text{T}_3$  in a dose designed to render the animals hyperthyroid (0.6  $\mu\text{g}/100$  g BW, twice daily) increased 5'DI activity to levels 10-fold greater than those observed in hypothyroid animals and two- to threefold greater than those present in a control group of euthyroid rats of the same age. The ability of  $\text{rT}_3$  and IOP to antagonize the stimulating effects of  $\text{T}_3$  were also examined (Fig. 3). 5'DI activity in hyperthyroid animals was unchanged after a single injection of  $\text{rT}_3$  (50  $\mu\text{g}/100$  g BW) or IOP (100  $\mu\text{g}/100$  g BW). However, injection of a single larger dose of IOP (4 mg/100 g BW), comparable in amount to that used in treating hyperthyroid patients with Graves' disease, resulted in a 78 and 85% decrease in  $V_{\text{max}}$  values in the liver and kidney, respectively. This inhibition by IOP in thyrotoxic animals resulted in levels of 5'DI activity that were less than or similar to




Figure 1. Effects of IOP on 5'DI activity in a broken kidney cell preparation. A kidney homogenate was prepared from a euthyroid animal and the diluted supernatant fraction was used to determine 5'DI activity. IOP, in the final concentrations indicated, was added to aliquots of the assay mixture before the quantitation of enzyme activity. A double reciprocal plot of the kinetic data demonstrates a competitive pattern of inhibition. A replot of the slope of the double reciprocal plots vs. the IOP concentration (*inset*) demonstrated a  $K_i$  value of 8  $\mu\text{M}$ . Similar results were obtained in a second experiment.




Figure 2. Effect of the *in vivo* administration of IOP on kidney 5'DI activity. Thyroidectomized rats were given an intraperitoneal injection of IOP (4 mg/100 g BW) or vehicle (control) and killed 3 h later. Kidney homogenates from individual animals were then prepared and 5'DI activity was determined in the diluted supernatant fractions. A double reciprocal plot of kinetic data from two representative animals demonstrates a noncompetitive pattern of inhibition.

those noted in euthyroid control rats. Again,  $K_m$  values in all groups were unchanged (Fig. 3), which suggests that the observed alterations in enzyme activity represented changes in the cellular content of active enzyme molecules. Kinetic data obtained in the liver from representative, individual animals from several of the treatment groups are shown in Fig. 4. On such plots, the  $V_{\text{max}}$  value is represented by the  $y$ -intercept, whereas the  $K_m$  value is equal to the negative value of the slope (26).

The time course of the *in vivo* inhibitory effects of IOP on 5'DI in hyperthyroid animals was investigated in another experiment in which rats were treated chronically with  $\text{T}_3$  (1  $\mu\text{g}/100$  g BW, *s.c.*, twice daily) and then were administered a single intravenous dose of IOP (4 mg/100 g BW) at 5, 12, 24, or 60 h before killing (Fig. 5). In the 24- and 60-h treatment groups,  $\text{T}_3$  administration was continued until 12 h before killing. Hyperthyroid animals again demonstrated significantly higher 5'DI activity in the liver and kidney when compared with euthyroid control rats. IOP administration resulted in an inhibition of  $V_{\text{max}}$  values in both tissues which was rapid in onset and prolonged in duration. The maximal inhibitory effects of 77 and 84% in liver and kidney, respectively, were similar to those noted previously and occurred at 5–12 h after


Table I. Effects of the *In Vivo* Administration of IOP on 5'DI Activity in the Kidney of Hypothyroid Rats

Treatment	$n^*$	$V_{\text{max}}$	$K_m$
		pmol/min · mg protein	$\mu\text{M}$
Control	6	13.3±0.7	0.10±0.01
IOP (0.04) <sup>‡</sup>	5	6.4±0.6 <sup>§</sup>	0.10±0.01
IOP (4)	5	4.5±0.5 <sup>§</sup>	0.11±0.03

\*  $n$ , number of rats.

<sup>‡</sup> IOP, in a single dose of 0.04 or 4 mg/100 g BW, *i.p.*, was administered 3 h before killing to rats that had been thyroidectomized 8 wk earlier. Data represent the mean±SE.


<sup>§</sup>  $P < 0.001$  vs. control (Dunnett's  $t$  test).



**Figure 3.** Effects of the chronic and acute in vivo administration of  $rT_3$ , IOP, and  $T_3$  on  $5'DI$  activity in the (A) liver and (B) kidney. Thyroidectomized rats received twice daily subcutaneous injections for 4 d according to the following protocol: (a) control, vehicle solution; (b)  $rT_3$ , 50  $\mu\text{g}/100$  g BW; (c) IOP, 100  $\mu\text{g}/100$  g BW; (d)  $T_3$  treatment, 0.6  $\mu\text{g}/100$  g BW. Animals were killed 12 h after the last injection and  $5'DI$  activity was quantified in diluted supernatant fractions of liver and kidney homogenates. 6 h before killing,  $T_3$ -treated animals received a single intravenous injection of vehicle (veh),  $rT_3$  (50  $\mu\text{g}/100$  g BW), or IOP (100  $\mu\text{g}$  or 4 mg/100 g BW). A group of euthyroid control rats of the same age served as an additional control group. Results depict the mean  $\pm$  SE of four to five animals per group. The insets at the base of each bar report the mean  $K_m$  value of each group expressed in  $\mu\text{mol}/\text{liter}$ . \* $P < 0.01$  vs. thyroidectomized control group;  $^{\ddagger}P < 0.01$  vs.  $T_3$  vehicle treatment group;  $^{\S}P < 0.05$  vs. thyroidectomized control;  $^{\parallel}P < 0.01$  vs.  $T_3$  vehicle treatment group and vs. euthyroid control group.

the IOP injection. Although partial recovery of  $5'DI$  activity was noted at the 60-h time point,  $V_{\text{max}}$  values were still significantly less (36 and 18% in liver and kidney, respectively) than those noted in the corresponding hyperthyroid control group.


**Effects of IOP on  $5'DI$  activity in the thyroid gland.**  $5'DI$  activity has been reported to be increased in the thyroid gland of patients with Graves' disease (36, 37). Similar increases in activity have been noted in the thyroid glands of rodents that were administered thyroid-stimulating hormone (TSH) (38) or Igs from patients with Graves' disease (39), or rendered hypothyroid by the chronic administration of MMI (40). To determine whether radiographic contrast agents inhibit  $5'DI$   $V_{\text{max}}$  levels in thyroid tissue, rats made goitrous by the inclusion of MMI in their drinking water were injected intravenously with a single dose of IOP (4 mg/100 g BW) and then killed 5 or 12 h later. In contrast to a previous report (40),  $5'DI$  activity in the thyroid glands of MMI-treated rats was not different from that determined in euthyroid control rats of the same age (Table II). IOP administration, however, resulted in a significant decrease in  $V_{\text{max}}$  levels at both time points. At 5 h after the IOP injection,



**Figure 4.** Hepatic  $5'DI$  activity, as analyzed by Eadie-Hofstee plots, of representative, individual animals from the experiment depicted in Fig. 3. On these plots, the  $y$ -intercept represents the  $V_{\text{max}}$  value, and the negative value of the slope indicates the  $K_m$ . A noncompetitive pattern of inhibition is demonstrated. Concentrations of  $rT_3$  on the abscissa are expressed in  $\mu\text{mol}/\text{liter}$ . Tx, thyroidectomized.

tion,  $5'DI$  activity was decreased by 29% ( $P < 0.05$ ), whereas at the 12-h time point activity was reduced by 52% ( $P < 0.005$ ). IOP administration did not alter  $K_m$  values in either treatment group. Thus, as is the case in the liver and the kidney, radiographic contrast agents inhibit  $5'DI$  in the thyroid gland in vivo by a noncompetitive mechanism.

**Regulation of  $5'DI$  in the Reuber FAO hepatoma cell line.** The suitability of Reuber FAO hepatoma cells to serve as a model system for studying the regulation of  $5'DI$  activity was investigated. Phenolic ring deiodinase activity was easily demonstrated in FAO cell sonicates using  $^{125}\text{I}$ - $rT_3$  as substrate. Characterization of this deiodinating process revealed the following: (a)  $^{125}\text{I}^-$  release from  $^{125}\text{I}$ - $rT_3$  was thiol-dependent with maximal product formation noted at DTT concentrations of 5–20 mM; (b) no  $^{125}\text{I}^-$  production was noted in cell sonicates incubated at 0–4°C or in sonicates previously heated to 80°C for 30 min; (c)  $^{125}\text{I}^-$  production varied linearly with sonicate protein content up to 2.5 mg/ml; (d) as determined by paper chromatography, equal quantities of  $\text{I}^-$  and 3,3'-diiodothyronine were formed from  $^{125}\text{I}$ - $rT_3$ ; (e) in the presence of 20 mM dithiothreitol, PTU at a concentration of 1 mM inhibited  $^{125}\text{I}^-$  production by > 99%; (f) using 1 nM  $^{125}\text{I}$ - $T_3$  as a substrate, no phenolic or tyrosyl ring deiodinating activity could be demonstrated in cell sonicates under routine assay conditions; (g)  $^{125}\text{I}^-$  formation decreased somewhat with time of assay incubation; calculated deiodinase activity at the end of a 40-min incubation period was decreased by  $\sim 30\%$  from that determined during a 10-min incubation. However, to allow accurate quantitation of reaction velocity under a variety of experimental conditions, a 40-min incubation period was typically used. Using  $^{125}\text{I}$ - $rT_3$  as substrate in sonicates prepared from FAO cells that were maintained in serum-free medium, saturable reaction kinetics were demonstrated for phenolic ring



**Figure 5.** Time course of the inhibitory effect of IOP on 5'DI activity in the (A) liver and (B) kidney of hyperthyroid rats. Euthyroid rats were rendered hyperthyroid by the subcutaneous injection of T<sub>3</sub> (1 μg/100 g BW twice daily) for 4 d. The hyperthyroid rats were then administered a single, intravenous dose of vehicle solution or IOP (4 mg/100 g BW) and killed 5, 12, 24, or 60 h later. T<sub>3</sub> injections were continued until 12 h before killing. Animals receiving a subcutaneous injection of vehicle twice daily for 4 d served as a euthyroid control group. Results depict the mean±SE of four to five animals per group. The insets at the base of each bar report the mean K<sub>m</sub> value of each group expressed in μmol/liter. \*P < 0.01 vs. corresponding hyperthyroid, vehicle group; †P < 0.05 vs. corresponding hyperthyroid, vehicle group.

**Table II.** Effects of the In Vivo Administration of IOP on 5'DI Activity in the Thyroid Gland of MMI-Treated Rats

Treatment	n*	V <sub>max</sub>	K <sub>m</sub>
		pmol/min · mg protein	μM
Euthyroid	7	163±13	0.09±0.01
MMI control†	6	137±10	0.12±0.01
MMI + IOP (5 h)	5	97±12§	0.11±0.01
MMI + IOP (12 h)	5	66±7	0.12±0.02

\* n, number of rats.

† Rats were rendered hypothyroid and goitrous by the inclusion of 200 μg/ml MMI in their drinking water for 4 wk. IOP, in a single dose of 4 mg/100 g BW, was administered intravenously 5 or 12 h before killing. MMI control animals were injected with an equivalent volume of vehicle. Rats maintained for the same period on regular drinking water served as a euthyroid group. Data represent the mean±SE.

§ P < 0.05 vs. MMI control.


|| P < 0.005 vs. MMI control. Statistical analysis was performed with Dunnett's t test.

deiodinase activity. In seven experiments, mean K<sub>m</sub> and V<sub>max</sub> values were 0.22±0.02 μM and 5.3±1.1 pmol <sup>125</sup>I<sup>-</sup> formed/min · mg protein, respectively. Reuber FAO hepatoma cells thus manifest a 5'-deiodinase process that has the typical characteristics of the type I activity normally found in rat liver and kidney.


The addition of IOP or rT<sub>3</sub> to the culture medium of FAO cells maintained under serum-free conditions resulted in a dose- and time-dependent inhibition of 5'DI activity that was characterized by a decrease in V<sub>max</sub> with no change in the K<sub>m</sub> value (Fig. 6). In three experiments in which cells were incubated for 18–40 h with 0.5 μM IOP, V<sub>max</sub> values were decreased by an average of 51±5%. At higher IOP concentrations (10 μM), inhibition was as great as 88%. The inhibitory effects of rT<sub>3</sub> were approximately equipotent to those of IOP. V<sub>max</sub> values were decreased by 36±6, 46±8, and 90±1% in three experiments in which cells were incubated with rT<sub>3</sub> at concentrations of 0.1, 1, and 3.3 μM, respectively. In other studies, a similar time course of 5'DI inhibition was noted for IOP and rT<sub>3</sub>; inhibitory effects were half-maximal at 3 h and maximal at 20 h after addition of the agents to the culture medium.

The dependency of the inhibitory effects of IOP and rT<sub>3</sub> on protein synthesis was investigated using FAO cells incubated with cycloheximide (Fig. 7). The addition of 50 μg/ml cycloheximide to the culture medium inhibited [<sup>3</sup>H]leucine incorporation into TCA-precipitated material by > 95%. In spite of this inhibition of protein synthesis, cycloheximide treatment for 6 h decreased 5'DI activity in FAO cells by only 5±2% (n = 4 experiments) compared with untreated control cells. Cycloheximide did not block the inhibitory effects of rT<sub>3</sub> and IOP on 5'DI activity. The addition of rT<sub>3</sub> (1 μM) or IOP (10 μM) to cycloheximide-treated cells resulted in a 42±9 and 53±10% decrease (P < 0.01 for either group vs. cycloheximide treatment alone) in enzyme activity, respectively, after a 6-h incubation. Thus, inhibition of 5'DI by these agents is due to an enhanced rate of enzyme inactivation and/or degradation.

A striking feature of the regulation of phenolic ring deiodination in GH<sub>3</sub> pituitary tumor cells is that exposure of intact




**Figure 6.** Effects of IOP and rT<sub>3</sub> on 5'DI activity in intact, cultured Reuber FAO hepatoma cells. FAO cells were grown to confluence in serum-containing medium, transferred, and maintained for 24 h in serum-free RPMI 1640 medium. IOP or rT<sub>3</sub>, in the final concentrations shown, were then added to the medium and the cells were cultured for an additional 20 h. Cells were then harvested and 5'DI activity was determined in supernatant fractions of cell sonicates. The data depicted are Eadie-Hofstee plots from a single, representative experiment. A noncompetitive pattern of inhibition is demonstrated. Concentrations of rT<sub>3</sub> on the abscissa are expressed in μmol/liter.



**Figure 7.** The effects of  $rT_3$  and IOP on 5'DI activity in intact, cultured FAO cells treated with cycloheximide. FAO cells were grown to confluence in serum-containing medium and then transferred and maintained for 24 h in serum-free RPMI 1640 medium. Cyclohexi-

amide (50  $\mu\text{g/ml}$ ), with or without  $rT_3$  (1  $\mu\text{M}$ ) or IOP (10  $\mu\text{M}$ ), was then added to the medium and the cells were cultured for an additional 6 h. Cells were then harvested, and 5'DI activity was determined in supernatant fractions of cell sonicates. FAO cells maintained in serum-free medium alone served as controls. The data depicted represent the mean  $\pm$  SE of the pooled results from four experiments. \* $P < 0.01$  vs. the cycloheximide group by Dunnett's  $t$  test.

cells to the sulfhydryl oxidizing agent diamide results in a rapid inactivation of 5'DII activity which mimicks the effects of  $rT_3$ , IOP, and other ligands (23). Analogous findings were demonstrated in FAO hepatoma cells treated with diamide (Fig. 8). In three experiments where intact cells were incubated for 3.5 h with 0.4 mM diamide, 5'DI  $V_{\text{max}}$  levels decreased by  $75 \pm 4\%$  ( $P < 0.025$ ), whereas  $K_m$  values were unaltered. Given the prior observation that the inhibition of protein synthesis for 6 h in FAO cells resulted in only a minimal loss of 5'DI activity, the rapidity of the diamide effect necessitates that the mechanism involved is an enhanced rate of enzyme inactivation. In these experiments, cells were maintained during the 3.5-h incubation period in glucose-free medium to inhibit the reformation of glutathione (41). 5'DI activity in control cells maintained in this medium did not differ from that noted in cells maintained concurrently in the same medium supplemented with glucose



**Figure 8.** Effect of diamide on 5'DI activity in intact, cultured FAO hepatoma cells. FAO cells were grown to confluence in serum-containing medium and then transferred and maintained for 24 h in serum-free RPMI 1640 medium. The medium was then changed to serum-free and glucose-free RPMI 1640, with or without diamide (0.4 mM), and the cells incubated for an additional 3.5 h. Cells were then washed and harvested with buffers containing 5 mM DTT and 5'DI activity was determined in the supernatant fractions of the cell sonicates. The data depicted are Eadie-Hofstee plots from a single representative experiment. A noncompetitive pattern of inhibition is demonstrated. Concentrations of  $rT_3$  on the abscissa are expressed in  $\mu\text{mol/liter}$ .

(2 mg/ml). The inhibitory effect of diamide in these experiments was not due to interference in the *in vitro* 5'DI assay system; the addition of 1 mM diamide to FAO cell sonicates did not alter 5'DI activity when 20 mM DTT was present in the reaction mixture.

## Discussion

The two enzymatic pathways that convert  $T_4$  to  $T_3$  (i.e., 5'DI and 5'DII) have been previously distinguished by differences in kinetic characteristics, susceptibility to inhibition by PTU, tissue distribution, and response to alterations in thyroid hormone status (42). Whereas hyperthyroidism in the rat leads to increased 5'DI activity (5, 6), the activity of 5'DII is markedly suppressed due to an unusual, and as yet incompletely understood process, which we have termed ligand-induced inactivation (23). The seminal finding of the present studies is that substrates and competitive inhibitors also induce the inactivation of 5'DI *in vivo*. This finding has significant implications for our understanding of the cellular mechanisms that regulate thyroid hormone economy.

**Inactivation of phenolic ring deiodinases.** In the experiments reported herein, the administration of iodinated compounds that are devoid of thyromimetic activity (i.e.,  $rT_3$  or IOP) to experimental animals or cultured cells resulted in a rapid and prolonged suppression of 5'DI activity that was characterized by a decrease in  $V_{\text{max}}$  with no change in  $K_m$ . These effects on 5'DI in hepatic and renal tissue are exactly analogous to those previously defined for 5'DII in the anterior pituitary gland and cerebral cortex (23). Furthermore, the inhibitory effects of ligands on these processes are independent of protein synthesis and are, therefore, secondary to an enhanced rate of enzyme inactivation and/or degradation. In the case of the 5'DI present in FAO cells,  $rT_3$  and IOP enhanced the rate of loss of enzyme activity by greater than 12-fold, assuming that the disappearance of activity after cycloheximide treatment is exponential.

Sato et al. (41) have previously reported that diamide treatment impairs the conversion of  $T_4$  to  $T_3$  by intact, cultured rat hepatocytes. Their studies, however, did not determine whether the decrease in  $T_3$  formation was due to a decrease in the availability of a necessary thiol cofactor or if it was secondary to an effect on 5'DI synthesis or inactivation. The present experiments demonstrate that this inhibitory effect of diamide on iodothyronine metabolism is due to a rapid inactivation of 5'DI. We have previously demonstrated that ligand-induced inactivation of 5'DII is also influenced by the cellular thiol/disulfide balance; the exposure of intact GH<sub>3</sub> cells to sulfhydryl oxidizing agents rapidly inactivates the enzyme, whereas exposure to sulfhydryl reducing agents protects against the substrate-induced loss of activity (23). Thus, the present finding that diamide rapidly inactivates 5'DI in intact FAO cells provides another important parallel in the regulation of the two phenolic ring deiodinase processes.

Of note, however, is that the 5'DI process appears to be considerably less sensitive than the 5'DII one to ligand-induced inactivation. Under experimental conditions where enzyme activity is increased (hypothyroidism for 5'DII; hyperthyroidism for 5'DI), a single injection of 0.04 mg IOP/100 g BW inactivates > 80% of 5'DII in the anterior pituitary gland and cerebral cortex (23), yet has no effect on 5'DI in the liver or

kidney (Fig. 3). Indeed, a 70–80% inhibition of 5'DI activity is only achieved when hypothyroid or hyperthyroid rats are administered a 100-fold larger dose of IOP (Table I and Fig. 3). Similarly, a single dose of rT<sub>3</sub> of 50 µg/100 g BW, which has been demonstrated by other investigators to inhibit 5'DII activity in the pituitary gland and cerebral cortex by > 90% (43), had no effect on 5'DI activity when administered to hyperthyroid animals in the present studies. Results from our cell culture studies provide additional evidence that 5'DI is less sensitive to ligand-induced inactivation. We have previously demonstrated that the concentration of IOP required to inhibit 5'DII activity by 50% in intact GH<sub>3</sub> cells that are maintained in serum-free medium is 0.005 µM (23). In the present experiments using FAO cells grown under analogous conditions, 50% inhibition of 5'DI required a medium IOP concentration of 0.5 µM.

Taken together, these data suggest that ~ 100-fold greater concentrations of ligand are required to inactivate 5'DI as compared with 5'DII. The reason for this marked difference in susceptibility to inactivation is uncertain, but could reflect tissue differences in either ligand concentration or the thiol/di-sulfide balance. Another intriguing possibility is suggested by our previous observation that the potency of a ligand in inactivating 5'DII in intact GH<sub>3</sub> cells is closely correlated with the ligand's K<sub>i</sub> value as determined in broken cell preparations and indicative of the affinity of the ligand for the enzyme's active site (23). The K<sub>i</sub> values of IOP for 5'DI and 5'DII are 8 µM (Fig. 1) and 0.05 µM (23), respectively, and therefore the affinity of 5'DI for this ligand is about two orders of magnitude less than the affinity of 5'DII. Thus, if the cellular mechanisms that inactivate 5'DI and 5'DII are similar, the lesser potency of IOP that inactivates the former enzyme may reflect the fact that higher concentrations are required to interact with the 5'DI active site and to initiate the inactivation process.

In addition to this difference in sensitivity, ligand-induced inactivation of 5'DI is somewhat slower than that noted for 5'DII. In intact GH<sub>3</sub> cells, maximal inactivation of 5'DII by ligands is noted after a 1–2-h incubation period (23), whereas in the FAO cells used in the present experiments, a 3-h incubation period with rT<sub>3</sub> or IOP resulted in only half-maximal inhibitory effects. Of further note is that compared with the 50-min half-life of 5'DII activity in GH<sub>3</sub> cells and other rat tissues (44), the turnover of 5'DI in FAO cells appears to be considerably slower, with only a 5% loss of enzyme activity after a 6-h treatment of cells with cycloheximide.

*Dual mechanism of control of 5'DI by iodinated compounds.* The present results demonstrate that iodothyronines and other iodinated compounds have complex regulatory effects on 5'DI in the liver and kidney. As demonstrated herein, and previously reported by other investigators (4–6), 5'DI is activated by the chronic administration of the metabolically active thyroid hormones T<sub>3</sub> or T<sub>4</sub>. Ligands for the enzyme which have little or no thyromimetic activity (i.e., rT<sub>3</sub> and IOP), however, inactivate this enzymatic process and can, when present in high concentrations, counteract the stimulatory effects of T<sub>3</sub> on 5'DI. Whether this activation and inactivation represent changes in enzyme synthesis and degradation remains uncertain.

Over the last three decades, investigators have observed that the administration of rT<sub>3</sub> to patients or laboratory animals, in amounts considerably larger than those used in the present study, counteracts the thyrotoxic state and antagonizes

the effects of T<sub>4</sub> (45–48). Such treatment has also been demonstrated to decrease hepatic T<sub>4</sub> to T<sub>3</sub> conversion (49), an effect which has previously been attributed to the competitive effect of rT<sub>3</sub> on T<sub>4</sub> deiodination that was noted *in vitro* (10, 50). Recently, Han et al. (51) reported that rT<sub>3</sub> also antagonizes the induction of 5'DI by insulin, cortisol, and T<sub>3</sub> in cultured fetal mouse liver cells. It was uncertain from their study, however, which processes mediated this rT<sub>3</sub> effect. The present findings provide a better understanding of the cellular mechanisms that underlie these observations. Our findings do not negate the possibility that rT<sub>3</sub>, when present in high concentrations, competes *in vivo* with T<sub>4</sub> as a substrate for phenolic ring deiodination. Rather, our results suggest that in so doing, the large ligand load presented by rT<sub>3</sub> rapidly inactivates 5'DI, and that this is likely to contribute significantly to the impairment observed in T<sub>3</sub> production.

*Radiographic contrast agents for the treatment for hyperthyroidism.* Radiographic contrast agents have been used successfully to treat the hyperthyroid state that accompanies Graves' disease in adults (13, 14, 17). Recent reports have also demonstrated the therapeutic value of administering these agents to patients with neonatal Graves' disease (52) and thyrotoxicosis factitia (53). IOP and NaIp offer several practical advantages when used as treatments for these conditions. They can be administered infrequently (13, 14), are generally well tolerated during chronic therapy (14), and rarely cause hypersensitivity reactions (52). In addition, the rapidity with which serum T<sub>3</sub> levels are lowered may have important clinical benefits (17).

The present findings provide new insights into the mechanisms whereby radiographic contrast agents alter thyroid hormone economy in thyrotoxicosis. The inactivating effect of IOP on 5'DI in hyperthyroid rats was noted to be rapid in onset and long-lasting in duration. Maximal inactivation was noted within 5 h, and significant effects persisted for 60 h after a single dose despite continued T<sub>3</sub> administration. In the clinical setting, the inhibitory effect would be likely to persist even longer, as the rapid lowering of serum and tissue T<sub>3</sub> levels would decrease the stimulus for 5'DI activation. These results correlate well with clinical observations that serum T<sub>3</sub> levels in hyperthyroid patients decrease 60% during the first 24 h of treatment with these agents (15, 16) and that they need be administered only once every 3 d (13).

In a recent study, Wang et al. (54) reported that a fixed dose of IOP (500 mg/d and equivalent to ~ 1 mg/100 g BW in the patients studied) resulted in the long term normalization of serum T<sub>3</sub> concentrations in only 45% of patients with Graves' disease. Given the present finding that the inactivating effects of radiographic contrast agents on 5'DI are dose-dependent, the therapeutic use of these agents in treating hyperthyroidism may require that the dosage be titrated to achieve optimal effects.

The thyroid gland in patients with Graves' disease demonstrates increased 5'DI activity (36, 37) and enhanced secretion of T<sub>3</sub> (55). Indeed, Laurberg (56) has recently demonstrated that both endogenous T<sub>4</sub> (that is, T<sub>4</sub> derived from thyroglobulin) and circulating T<sub>4</sub> are deiodinated to T<sub>3</sub> in this organ. The present finding that 5'DI in the thyroid gland is also subject to rapid inactivation by IOP provides an explanation for the previous observations that radiographic contrast agents inhibit thyroidal T<sub>3</sub> secretion *in vivo* (57) and 5'DI activity *in vitro* (38, 58).

In conclusion, we have demonstrated that 5'DI is subject to ligand-induced inactivation, an observation which corrects prior misconceptions concerning the mechanism whereby iodothyronines and other iodinated compounds inhibit T<sub>4</sub> to T<sub>3</sub> conversion in vivo. Although this inactivation process appears to be analogous to that previously delineated for 5'DII, the role of this mechanism in regulating the activity of these two enzymatic pathways appears to differ. Whereas inactivation by substrate is the principal mechanism controlling 5'DII activity (44), it seems unlikely that this process influences 5'DI activity under physiologic or even pathologic conditions; the predominant effect of T<sub>4</sub> on 5'DI is one of activation (5, 6, 59) and rT<sub>3</sub> concentrations are probably insufficient to exert a significant inactivating effect (49). However, the inactivation of 5'DI is of major pharmacologic importance when the radiographic contrast agents are used to treat hyperthyroid patients. At present, the biochemical processes that mediate the inactivation of the phenolic ring deiodinases remain uncertain. A greater understanding of this unusual mechanism of enzyme regulation is likely to have important theoretical and clinical consequences.

### Acknowledgments

The author thanks Ms. Janet Fatherly for her secretarial assistance, Dr. Lee Witters for his advice and support, and Dr. Valerie Anne Galton for her critical review of the manuscript.

This investigation was supported by a grant from the Hitchcock Foundation (Hanover, NH). The author is the recipient of a Clinical Investigator Award (DK-01389) from the National Institute of Diabetes and Digestive and Kidney Diseases.

### References

- Kaplan, M. M., and R. D. Utiger. 1978. Diagnosis of hyperthyroidism. *Clin. Endocrinol. Metab.* 7:97-113.
- Kaplan, M. M. 1986. Regulatory influences on iodothyronine deiodination in animal tissues. In *Thyroid Hormone Metabolism*. G. Hennemann, editor. Marcel Dekker, Inc., New York. 231-253.
- van Doorn, J., D. van der Heide, and F. Roelfsema. 1984. The contribution of local thyroxine monodeiodination to intracellular 3,5,3'-triiodothyronine in several tissues of hyperthyroid rats at isotopic equilibrium. *Endocrinology*. 115:174-182.
- Jennings, A. S., F. L. Crutchfield, and M. B. Dratman. 1984. Effect of hypothyroidism and hyperthyroidism on triiodothyronine production in perfused rat liver. *Endocrinology*. 114:992-997.
- Kaplan, M. M. 1979. Changes in the particulate subcellular component of hepatic thyroxine-5'-monodeiodinase in hyperthyroid and hypothyroid rats. *Endocrinology*. 105:548-554.
- Smallridge, R. C., L. Wartofsky, and K. D. Burman. 1982. The effect of experimental hyperthyroidism and hypothyroidism on 5'-monodeiodination of 3,3',5'-triiodothyronine and 3',5'-diiodothyronine by rat liver and kidney. *Endocrinology*. 111:2066-2069.
- Burgi, H., C. Wimpfheimer, A. Burger, W. Zaunbauer, H. Rosler, and T. Lemarchand-Beraud. 1976. Changes of circulating thyroxine, triiodothyronine and reverse triiodothyronine after radiographic contrast agents. *J. Clin. Endocrinol. & Metab.* 43:1203-1210.
- Kleinmann, R. E., A. G. Vagenakis, and L. E. Braverman. 1980. The effect of iopanoic acid on the regulation of thyrotropin secretion in euthyroid subjects. *J. Clin. Endocrinol. & Metab.* 51:399-403.
- England, M. L., J. M. Hershman, A. E. Pekary, D. G. Feng, and J. J. DiStefano. 1984. T<sub>4</sub> and T<sub>3</sub> kinetics in patients taking sodium ipodate. *Program 60th Annu. Meeting Am. Thyroid Assoc.* T-6. (Abstr.)
- Kaplan, M. M., and R. D. Utiger. 1978. Iodothyronine metabolism in rat liver homogenates. *J. Clin. Invest.* 61:459-471.
- Obregon, M. J., A. Pascual, J. Mallol, G. Morreale de Escobar, and F. Escobar del Rey. 1980. Evidence against a major role of L-thyroxine at the pituitary level: studies in rats treated with iopanoic acid (Tepeaque). *Endocrinology*. 106:1827-1836.
- Silva, J. E., J. L. Leonard, F. R. Crantz, and P. R. Larsen. 1982. Evidence for two tissue-specific pathways for in vivo thyroxine 5'-deiodination in the rat. *J. Clin. Invest.* 69:1176-1184.
- Wu, S.-Y., I. J. Chopra, D. H. Solomon, and D. E. Johnson. 1978. The effect of repeated administration of ipodate (Oragrafin) in hyperthyroidism. *J. Clin. Endocrinol. & Metab.* 47:1358-1362.
- Shen, D.-C., S.-Y. Wu, I. J. Chopra, H.-W. Huang, L.-R. Shian, T.-Y. Bian, C.-Y. Jeng, and D. H. Solomon. 1985. Long term treatment of Graves' hyperthyroidism with sodium ipodate. *J. Clin. Endocrinol. & Metab.* 61:723-727.
- Roti, E., G. Robuschi, A. Manfredi, L. D'Amato, E. Gardini, M. Salvi, M. Montermini, A. L. Barlli, A. Gnudi, and L. E. Braverman. 1985. Comparative effects of sodium ipodate and iodide on serum thyroid hormone concentrations in patients with Graves' disease. *Clin. Endocrinol.* 22:489-496.
- Wu, S.-Y., T.-P. Shyh, I. J. Chopra, D. H. Solomon, H.-W. Huang, and P.-C. Chu. 1982. Comparison of sodium ipodate (Oragrafin) and propylthiouracil in early treatment of hyperthyroidism. *J. Clin. Endocrinol. & Metab.* 54:630-634.
- Seclen, S. N., E. A. Pretell, F. A. Tapia, J. M. Sosa, and R. Barreto. 1986. Rapid amelioration of severe cardiovascular complications of thyrotoxic patients by sodium ipodate. In *Frontiers in Thyroidology*. G. Medeiros-Neto and E. Gaitan, editors. Plenum Medical Book Company, New York. 1101-1105.
- Chopra, I. J., D. H. Solomon, U. Chopra, S. Wu, D. A. Fisher, and Y. Nakamura. 1978. Pathways of metabolism of thyroid hormones. *Recent Prog. Horm. Res.* 34:521-556.
- Chopra, I. J. 1978. Inhibition of outer ring monodeiodination of T<sub>4</sub> and reverse T<sub>3</sub> (rT<sub>3</sub>) by some radiographic contrast agents. *Clin. Res.* 26:303A. (Abstr.)
- Fekkes, D., G. Hennemann, and T. J. Visser. 1982. One enzyme for the 5'-deiodination of 3,3',5'-triiodothyronine and 3',5'-diiodothyronine in rat liver. *Biochem. Pharmacol.* 31:1705-1709.
- Courtin, F., G. Pelletier, and P. Walker. 1985. Subcellular localization of thyroxine 5'-deiodinase activity in bovine anterior pituitary. *Endocrinology*. 117:2527-2533.
- Goswami, A., and I. N. Rosenberg. 1986. Iodothyronine 5'-deiodinase in brown adipose tissue: thiol activation and propylthiouracil inhibition. *Endocrinology*. 119:916-923.
- St. Germain, D. L. 1988. The effects and interactions of substrates, inhibitors, and the cellular thiol:disulfide balance on the regulation of iodothyronine 5'-deiodinase. *Endocrinology*. 122:1860-1868.
- Leonard, J. L., and I. N. Rosenberg. 1980. Iodothyronine 5'-deiodinase from rat kidney: substrate specificity and the 5'-deiodination of reverse triiodothyronine. *Endocrinology*. 107:1376-1383.
- McCann, U. D., E. A. Shaw, and M. M. Kaplan. 1984. Iodothyronine deiodination reaction types in several rat tissues: effects of age, thyroid status, and glucocorticoid treatment. *Endocrinology*. 114:1513-1521.
- Hofstee, B. H. J. 1952. On the evaluation of the constants V<sub>m</sub> and K<sub>m</sub> in enzyme reactions. *Science (Wash. DC)*. 116:329-331.
- Lee, H.-J., and I. B. Wilson. 1971. Enzymic parameters: measurement of V and K<sub>m</sub>. *Biochim. Biophys. Acta.* 242:519-522.
- Segal, I. H. 1975. *Enzyme Kinetics*. John Wiley & Sons, Inc., New York. 100-109.
- Scornik, O. A., M. L. S. Ledbetter, and J. S. Malter. 1980. Role of aminoacylation of histidyl-tRNA in the regulation of protein degradation in Chinese hamster ovary cells. *J. Biol. Chem.* 255:6322-6329.
- Galton, V. A., and A. Hiebert. 1987. The ontogeny of the enzyme systems for the 5'- and 5-deiodination of thyroid hormones in chick embryo liver. *Endocrinology*. 120:2604-2610.
- van Doorn, J., F. Roelfsema, and D. van der Heide. 1982. Contribution from local conversion of thyroxine to 3,5,3'-triiodothy-



- ronine to intracellular 3,5,3'-triiodothyronine in several organs in hypothyroid rats at isotope equilibrium. *Acta Endocrinol.* 101:386-396.
32. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* 193:265-275.
33. Bensadoun, A., and D. Weinstein. 1976. Assay of proteins in the presence of interfering materials. *Anal. Biochem.* 70:241-250.
34. Godfrey, K. 1985. Comparing the means of several groups. *N. Engl. J. Med.* 313:1450-1456.
35. Winer, B. J. 1971. *Statistical Principles in Experimental Design*. 2nd edition. McGraw-Hill Book Co., New York. 201-204.
36. Ishii, H., M. Inada, K. Tanaka, Y. Mashio, K. Naito, M. Nishikawa, and H. Imura. 1981. Triiodothyronine generation from thyroxine in human thyroid: enhanced conversion in Graves' thyroid tissue. *J. Clin. Endocrinol. & Metab.* 52:1211-1217.
37. Sugawara, M., R. Lau, H. L. Wasser, A. M. Nelson, K. Kuma, and J. M. Hershman. 1984. Thyroid T4 5'-deiodinase activity in normal and abnormal human thyroid glands. *Metab. Clin. Exp.* 33:332-336.
38. Wu, S.-Y., R. Reggio, and W. H. Florsheim. 1985. Characterization of thyrotropin-induced increase in iodothyronine monodeiodinating activity in mice. *Endocrinology.* 116:901-908.
39. Wu, S.-Y., R. Reggio, W. Florsheim, I. J. Chopra, and D. H. Solomon. 1987. Stimulation of thyroidal iodothyronine 5'-monodeiodinase by long-acting thyroid stimulator (LATS). *Acta Endocrinol.* 114:193-200.
40. Erickson, V. J., R. R. Cavalieri, and L. L. Rosenberg. 1982. Thyroxine-5'-deiodinase of rat thyroid, but not that of liver, is dependent on thyrotropin. *Endocrinology.* 111:434-440.
41. Sato, K., H. Mimura, K. Wakai, N. Tomori, T. Tsushima, and K. Shizume. 1983. Modulating effect of glutathione disulfide on thyroxine-5'-deiodination by rat hepatocytes in primary culture: effect of glucose. *Endocrinology.* 113:878-886.
42. Kaplan, M. M. 1984. The role of thyroid hormone deiodination in the regulation of hypothalamo-pituitary function. *Neuroendocrinology.* 38:254-260.
43. Silva, J. E., and J. L. Leonard. 1985. Regulation of rat cerebrocortical and adenohipophyseal type II 5'-deiodinase by thyroxine, triiodothyronine, and reverse triiodothyronine. *Endocrinology.* 116:1627-1635.
44. Leonard, J. L., J. E. Silva, M. M. Kaplan, S. A. Mellen, T. J. Visser, and P. R. Larsen. 1984. Acute posttranscriptional regulation of cerebrocortical and pituitary iodothyronine 5'-deiodinases by thyroid hormone. *Endocrinology.* 114:998-1004.
45. Pittman, C. S., and S. B. Barker. 1959. Inhibition of thyroxine action by 3,3',5'-triiodothyronine. *Endocrinology.* 64:466-468.
46. Benua, R. S., S. Kumaoka, R. D. Leeper, and R. W. Rawson. 1959. The effect of dl-3,3',5'-triiodothyronine in Graves' disease. *J. Clin. Endocrinol. & Metab.* 19:1344-1346.
47. Pittman, C. S., and S. B. Barker. 1959. Antithyroxine effects of some thyroxine analogues. *Am. J. Physiol.* 197:1271-1274.
48. Pittman, J. A., J. O. Tingley, J. F. Nickerson, and S. R. Hill, Jr. 1960. Antimetabolic activity of 3,3',5'-triiodo-DL-thyronine in man. *Metab. Clin. Exp.* 9:293-295.
49. Coiro, V., A. Harris, H. M. Goodman, A. Vagenakis, and L. Braverman. 1980. Effect of pharmacological quantities of infused 3,3',5'-triiodothyronine on thyroxine monodeiodination to 3,5,3'-triiodothyronine. *Endocrinology.* 106:68-75.
50. Chopra, I. J. 1977. A study of extrathyroidal conversion of thyroxine (T<sub>4</sub>) to 3,3',5'-triiodothyronine (T<sub>3</sub>) *in vitro*. *Endocrinology.* 101:453-463.
51. Han, D. C., K. Sato, Y. Fujii, T. Tsushima, and K. Shizume. 1986. 3,3',5'-triiodothyronine inhibits iodothyronine-5'-deiodinating activity induced by 3,5,3'-triiodothyronine at equimolar concentrations in cultured fetal mouse liver. *Endocrinology.* 119:1076-1082.
52. Karpman, B. A., B. Rapoport, S. Filetti, and D. A. Fisher. 1987. Treatment of neonatal hyperthyroidism due to Graves' disease with sodium ipodate. *J. Clin. Endocrinol. & Metab.* 64:119-123.
53. Ermans, A.-M., and P. Bourdoux. 1986. Long-term administration of iopanoic acid in a case of severe thyrotoxicosis factitia. *In Frontiers in Thyroidology*. G. Medeiros-Neto and E. Gaitan, editors. Plenum Medical Book Company, New York. 1137-1142.
54. Wang, Y., C. Tsou, W. Lin, and J. M. Hershman. 1987. Long term treatment of Graves' disease with iopanoic acid (Telepaque). *J. Clin. Endocrinol. & Metab.* 65:679-682.
55. Laurberg, P. 1984. Mechanisms governing the relative proportions of thyroxine and 3,5,3'-triiodothyronine in thyroid secretion. *Metab. Clin. Exp.* 33:379-392.
56. Laurberg, P. 1986. Thyroxine entering the thyroid gland via the vascular bed may leave the gland as triiodothyronines. Studies with perfused dog thyroid lobes. *Endocrinology.* 118:895-900.
57. Laurberg, P. 1982. The effect of some iodine-containing radiocontrast agents on iodothyronine secretion from perfused canine thyroid. *Endocrinology.* 111:1904-1908.
58. Laurberg, P., and N. Boye. 1982. Outer and inner ring monodeiodination of thyroxine by dog thyroid and liver: a comparative study using a particulate cell fraction. *Endocrinology.* 110:2124-2130.
59. Kaplan, M. M., and R. D. Utiger. 1978. Iodothyronine metabolism in liver and kidney homogenates from hyperthyroid and hypothyroid rats. *Endocrinology.* 103:156-161.